Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announc...
Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a vent...
Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, wh...
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal paras...
GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s revolutionary nCommand Lite technology, aimed at mitig...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
Isansys Lifecare, led by the visionary Keith Errey, has gained recognition in the global healthcare technology market, particularly through its suc...
“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bemped...
QIAGEN has announced a collaborative effort with the International Panel Physicians Association (IPPA) to bolster awareness of tuberculosis (TB) screening ...
Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy conditions, has achieved a significant milestone ...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal a...
The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, a...
© 2025 Biopharma Boardroom. All Rights Reserved.
